SciFi Advisor
Event-driven, biotech, healthcare, small-cap

Prothena Offers A Strong Pipeline Beyond Amyloidosis

A few weeks ago, I wrote an article about a relatively new biotech company known as Prothena (NASDAQ:PRTA), which highlighted its development efforts towards a disease-modifying antibody treatment for amyloidoses, NEOD001. Since then, the stock has gained 25%, closing on June 19 with a price of $12.76 and a market capitalization of $223M. The company's shares have gained 85% since the Elan spin-out began trading publicly in late 2012. Yet, even with this impressive run, I believe Prothena still has upside based not only on its amyloidosis program, but on its strong pipeline of disease-modifying antibodies. Prothena's second program in development is PRX002, a treatment for Parkinson's disease, and the company is developing PRX003 as a potential treatment...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details